Addex Therapeutics (ADXN) vs Enlivex (ENLV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Addex Therapeutics is the larger company by market cap ($5.6 million vs $5.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADXN | ENLV |
|---|---|---|
| Share price | $3.22 | $0.254 |
| Market cap | $5.64M | $5.06M |
| 1-day change | +1.21% | -8.30% |
| P/E ratio (TTM) | — | 0.00 |
| EPS (TTM) | $-7.56 | $494.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.97 | $27.15 |
| 52-week low | $2.56 | $0.224 |
| Distance from 52-week high | -73.11% | -99.06% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +31396.06% |
| Average volume | 138.20K | 950.55K |
| Shares outstanding | 1.75M | 19.91M |
| Employees | 3 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Addex Therapeutics
ADXN stock →Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
About Enlivex
ENLV stock →Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
ADXN vs ENLV FAQ
Which is bigger, Addex Therapeutics or Enlivex?
Addex Therapeutics (ADXN) is larger, with a market capitalization of $5.64M compared with $5.06M for Enlivex (ENLV).
Are Addex Therapeutics and Enlivex in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.